No Data
No Data
Ryvu Therapeutics Presents Clinical and Preclinical Data on RVU120 at the 2024 European Hematology Association Congress
RVU120 as a single agent showed clinical benefit in heavily pretreated patients with AML and HR-MDS in the Phase 1 RIVER-51 study (CLI120-001). The strongest evidence of benefit was observed in patie
Exelixis, Inc. (NASDAQ:EXEL) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Most readers would already know that Exelixis' (NASDAQ:EXEL) stock increased by 4.6% over the past month. However, we decided to study the company's mixed-bag of fundamentals to assess what this cou
Insider Sale: Director Jack Wyszomierski Sells Shares of Exelixis Inc (EXEL)
Exelixis(EXEL.US) Director Sells US$182.31K in Common Stock
$Exelixis(EXEL.US)$ Director WYSZOMIERSKI JACK L sold 8,287 shares of common stock on Jun 4, 2024 at an average price of $22 for a total value of $182.31K.Source: Announcement What is statement of cha
Form 144 | Exelixis(EXEL.US) Director Proposes to Sell 182.34K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 4, $Exelixis(EXEL.US)$ Director JACK L WYSZOMIERSKI intends to sell 8,287 shares of its common stock on Jun 4, with a total market value of approximately $182.34K. JACK L
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
No Data